Drugs / drospirenone
drospirenone
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed | Japan (PMDA) | — | contraception | 2024-06-24 | “LF111（一般名：ドロスピレノン、以下「本剤」）について、避 妊を適応症として本日付けで製造販売承認申請を行いました” aska-pharma.co.jp ↗ |
| Approved | EU (EMA) | Lydisilka | — | 2021-05-19 | europa.eu ↗ |
| Approved | US (FDA) | YASMIN | — | 2001-05-11 | fda.gov ↗ |
Trials 87 · started per year
today
US approved 2001
EU approved 2021
1
4
6
2
1
7
6
1
1
2
2
3
2
1
8
4
1
1
3
4
3
7
8
5
4
2001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03037944 | Mar 2016 → Dec 2017 | adenomyosis | Ain Shams Maternity Hospital | Unknown | No outcome recorded |
| Phase 121 trials | ||||||
| Phase 1 | NCT07792408 | Sep 2026 → Mar 2027 expected | autosomal dominant polycystic kidney disease | Vertex Pharmaceuticals Incorporated | Recruiting | No outcome recorded |
| Phase 1 | NCT07340190 | Jun 2026 → Mar 2028 expected | cancer | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1 | NCT07235774 | Nov 2025 → Mar 2026 | — | Servier | Completed | No outcome recorded |
| Phase 1 | NCT07074327 | Jul 2025 → Feb 2026 | autosomal dominant polycystic kidney disease | Vertex Pharmaceuticals Incorporated | Completed | No outcome recorded |
| Phase 1 | NCT07181343 | May → Jun 2025 | psoriasis | Hansoh BioMedical R&D Company | Completed | No outcome recorded |
| Phase 1 | NCT06820307 | Feb → Apr 2025 | — | Vertex Pharmaceuticals Incorporated | Completed | No outcome recorded |
| Phase 1 | NCT06233058 | Mar → Apr 2024 | — | Bio-innova Co., Ltd | Unknown | No outcome recorded |
| Phase 1 | NCT06233071 | Feb → Apr 2024 | — | Bio-innova Co., Ltd | Unknown | No outcome recorded |
| Phase 1 | NCT06250205 | Feb → Apr 2024 | — | NewAmsterdam Pharma | Completed | No outcome recorded |
| Phase 1 | NCT06039826 | Sep 2023 → Jul 2024 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT05934942 | Sep 2023 → Feb 2024 | — | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 1 | NCT05985590 | Aug → Dec 2023 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT05706753 | Jan → Jul 2023 | — | Janssen Pharmaceutica N.V., Belgium | Completed | No outcome recorded |
| Phase 1 | NCT05677035 | Jan → Jun 2022 | — | Hyundai Pharm | Completed | No outcome recorded |
| Phase 1 | NCT03890341 | Jun → Aug 2021 | — | Janssen Research & Development, LLC | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT03512860 | Apr → Oct 2018 | — | Estetra | Completed | No outcome recorded |
| Phase 1 | NCT03353857 | Nov 2017 → Jul 2018 | — | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT03126097 | Apr → May 2017 | — | Janssen Research & Development, LLC | Terminated | No outcome recorded |
| Phase 1 | NCT03111511 | Mar → Aug 2017 | — | Janssen Sciences Ireland UC | Completed | No outcome recorded |
| Phase 1 | NCT02885454 | Aug → Dec 2016 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT02852681 | Aug → Oct 2015 | — | Estetra | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT06608186 | Oct 2024 → Jan 2025 | polycystic ovary syndrome | Ahmed Saad | Completed | No outcome recorded |
| Phase 1/2 | NCT06345560 | Apr 2024 → Jul 2026 overdue | — | Chulalongkorn University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT02957630 | Sep 2016 → Oct 2017 | — | Estetra | Completed | No outcome recorded |
| Phase 29 trials · 1 missed | ||||||
| Phase 2 | NCT05098574 | Feb 2023 → Apr 2024 | bipolar disorder, premenstrual dysphoric disorder | St. Joseph's Healthcare Hamilton | Completed | No outcome recorded |
| Phase 2 | NCT05675644 | Feb → Dec 2023 | — | University of Colorado, Denver | Unknown | No outcome recorded |
| Phase 2 | NCT04278755 | Sep 2020 → May 2022 | binge eating disorder, bulimia nervosa | University of North Carolina, Chapel Hill | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00722800 | Oct 2008 → Dec 2011 | hidradenitis suppurativa | Massachusetts General Hospital | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00653614 | Mar 2008 → Jun 2009 | — | Bayer | Completed | No outcome recorded |
| Phase 2 | NCT00631124 | Feb → Oct 2008 | — | Bayer | Completed | No outcome recorded |
| Phase 2 | NCT00420342 | Jan 2007 → Sep 2008 | hypertensive disorder | Bayer | Completed | Missed primary |
| Phase 2 | NCT00089414 | Jul 2004 → Jun 2010 | depressive disorder, premenstrual dysphoric disorder | National Institute of Mental Health (NIMH) | Terminated | No outcome recorded |
| Phase 2 | NCT00673686 | May 2004 → Feb 2005 | — | Bayer | Completed | No outcome recorded |
| Phase 2/32 trials · 1 met primary | ||||||
| Phase 2/3 | NCT00511797 | Jul 2007 → Jan 2009 | dysmenorrhea | Bayer | Completed | Met primary |
| Phase 2/3 | NCT00461305 | Feb 2007 → Jan 2009 | dysmenorrhea | Bayer | Completed | No outcome recorded |
| Phase 327 trials · 8 met primary | ||||||
| Phase 3 | NCT07536763 | Jul 2026 → Jun 2029 expected | — | Dr. Hang Wun Raymond Li | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05461573 | Aug 2022 → Aug 2024 | — | Insud Pharma | Completed | No outcome recorded |
| Phase 3 | NCT04792385 | Dec 2020 → Nov 2023 | — | Estetra | Completed | No outcome recorded |
| Phase 3 | NCT03843736 | Feb 2019 → Jun 2020 | polycystic ovary syndrome | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT02817841 | Aug 2016 → Oct 2018 | — | Estetra | Completed | No outcome recorded |
| Phase 3 | NCT02817828 | Jun 2016 → Apr 2018 | — | Estetra | Completed | No outcome recorded |
| Phase 3 | NCT02617537 | Jan 2016 → Sep 2017 | dysmenorrhea | Bayer | Withdrawn | No outcome recorded |
| Phase 3 | NCT02269241 | Oct 2014 → Oct 2017 | — | Laboratories Leon Farma, S.A. | Completed | Met primary |
| Phase 3 | NCT01892904 | Jul 2013 → Jan 2015 | dysmenorrhea | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT01331655 | Apr 2013 → Nov 2014 | — | Bayer | Withdrawn | No outcome recorded |
| Phase 3 | NCT01697111 | Oct 2012 → Mar 2014 | endometriosis | Bayer | Completed | Met primary |
| Phase 3 | NCT01076582 | Apr 2010 → Oct 2011 | — | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00824187 | Jan 2009 → Jan 2011 | premenstrual dysphoric disorder | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00818519 | Dec 2008 → May 2010 | acne | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00569244 | Dec 2007 → Dec 2009 | primary dysmenorrhea | Bayer | Completed | Met primary |
| Phase 3 | NCT00567164 | Oct 2007 → Nov 2009 | anovulation | Bayer | Completed | Met primary |
| Phase 3 | NCT00522873 | Aug 2007 → Aug 2009 | — | Bayer | Completed | Met primary |
| Phase 3 | NCT00446199 | Mar 2007 → Oct 2008 | — | Bayer | Completed | Met primary |
| Phase 3 | NCT00266032 | Dec 2005 → Oct 2008 | — | Bayer | Completed | Met primary |
| Phase 3 | NCT00651599 | Jul 2004 → May 2005 | vasomotor rhinitis | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00102141 | Apr 2004 → Jul 2005 | essential hypertension | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00624130 | Mar 2004 → Jun 2005 | — | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00185484 | Mar 2004 → Jan 2006 | — | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00185419 | Nov 2003 → Mar 2006 | — | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00651469 | Jan 2003 → Jul 2004 | acne | Bayer | Completed | Met primary |
| Phase 3 | NCT00656981 | Jan 2003 → Jun 2004 | acne | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00367276 | Dec 2002 → May 2004 | — | Bayer | Completed | No outcome recorded |
| Phase 414 trials · 1 met primary | ||||||
| Phase 4 | NCT07293728 | Jul → Dec 2026 expected | preeclampsia | Oregon Health and Science University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05837624 | Dec 2024 → Nov 2026 expected | ovarian endometriosis | Andrew Zakhari | Recruiting | No outcome recorded |
| Phase 4 | NCT06324851 | Jan → Aug 2023 | endometrial polyp | University of Palermo | Completed | No outcome recorded |
| Phase 4 | NCT05303636 | Mar 2022 → Dec 2027 expected | disease of bone structure | Insud Pharma | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04965116 | Oct 2021 → Nov 2022 | — | University of California, San Diego | Completed | No outcome recorded |
| Phase 4 | NCT05340634 | Apr 2020 → Feb 2022 | polycystic ovary syndrome | Margan Biotech | Completed | No outcome recorded |
| Phase 4 | NCT02710708 | May 2016 → Jul 2018 | — | Bayer | Completed | No outcome recorded |
| Phase 4 | NCT02237131 | Apr 2014 → Apr 2015 | dysmenorrhea, ovarian endometriosis, pelvis syndrome | University of Athens | Unknown | No outcome recorded |
| Phase 4 | NCT02027337 | Dec 2013 → Mar 2015 | menstrual disorder, polycystic ovary syndrome | Tyumen State Medical Academy | Unknown | No outcome recorded |
| Phase 4 | NCT01608698 | Jun 2012 → Jan 2016 | — | Mahidol University | Unknown | Met primary |
| Phase 4 | NCT01360996 | Aug 2011 → Feb 2015 | polycystic ovary syndrome | Woman's | Completed | No outcome recorded |
| Phase 4 | NCT00785317 | Nov 2008 → Oct 2009 | — | Karolinska Institutet | Unknown | No outcome recorded |
| Phase 4 | NCT00185328 | Sep 2005 → Dec 2006 | — | Bayer | Completed | No outcome recorded |
| Phase 4 | NCT00651846 | Jun 2003 → Feb 2005 | — | Bayer | Completed | No outcome recorded |
| Phase not applicable10 trials · 2 missed | ||||||
| — | NCT07127458 | Aug 2025 → Mar 2026 | polycystic ovary syndrome | Ege University | Completed | No outcome recorded |
| — | NCT06396221 | May → Sep 2024 | anovulation | Chulalongkorn University | Completed | No outcome recorded |
| — | NCT06345586 | Apr 2024 → Jul 2026 overdue | — | Chulalongkorn University | Recruiting | No outcome recorded |
| — | NCT04831151 | Mar 2021 → Mar 2023 | polycystic ovary syndrome | Inonu University | Unknown | No outcome recorded |
| — | NCT04984070 | Jan 2021 → Dec 2023 | mixed anxiety and depressive disorder, polycystic ovary syndrome | Fudan University | Unknown | No outcome recorded |
| — | NCT02865187 | Feb 2017 → Mar 2020 | polycystic ovary syndrome, sexual disorder | Wright State University | Completed | Missed primary |
| — | NCT02757469 | May 2016 → May 2020 | premature menopause | Navy General Hospital, Beijing | Unknown | No outcome recorded |
| — | NCT01459445 | Feb → Jun 2011 | polycystic ovary syndrome | Iuliu Hatieganu University of Medicine and Pharmacy | Unknown | Mixed |
| — | NCT00633360 | Feb 2008 → May 2011 | depressive disorder, premenstrual tension | Massachusetts General Hospital | Completed | Missed primary |
| — | NCT00442689 | Jul 2006 → Nov 2012 | metabolic syndrome X, polycystic ovary syndrome | Northwestern University | Completed | No outcome recorded |
| Comparator or background therapy40 trials | ||||||
| Phase 1 | NCT02874248 Comparator | May → Nov 2016 | — | Estetra | Completed | No outcome recorded |
| Phase 1 | NCT01291004 Comparator | Jan 2011 → Mar 2012 | — | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01258660 Background | Dec 2006 → Jan 2008 | — | Bayer | Completed | No outcome recorded |
| Phase 2 | NCT03091595 Comparator | Feb 2017 → Jun 2018 | — | Estetra | Completed | No outcome recorded |
| Phase 2/3 | NCT04256200 Comparator | Feb 2017 → Nov 2021 | endometriosis | American University of Beirut Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT03074045 Comparator | Mar 2017 → Sep 2018 | — | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT02562053 Comparator | Oct 2015 → Sep 2017 | premenstrual tension | Cairo University | Unknown | No outcome recorded |
| Phase 3 | NCT02488538 Comparator | Jul 2015 → Jul 2017 | premenstrual tension | Cairo University | Unknown | No outcome recorded |
| Phase 3 | NCT01902264 Background | Aug 2013 → Feb 2015 | — | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT01277211 Comparator | Sep 2011 → Sep 2013 | — | Organon and Co | Completed | Missed primary |
| Phase 3 | NCT01254292 Comparator | Jan 2011 → Jan 2013 | — | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT01590849 Comparator | Jan 2011 → May 2012 | — | Instituto do Coracao | Unknown | No outcome recorded |
| Phase 3 | NCT01257984 Background | Dec 2010 → Aug 2012 | — | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00722761 Comparator | Apr 2009 → Apr 2012 | acne | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00819312 Comparator | Dec 2008 → Jan 2011 | — | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT01581814 Comparator | Oct 2008 → Jul 2011 | polycystic ovary syndrome | Catholic University of the Sacred Heart | Completed | No outcome recorded |
| Phase 3 | NCT00468481 Comparator | Apr 2007 → Aug 2008 | neural tube defect | Bayer | Completed | Met primary |
| Phase 3 | NCT00948402 Comparator | Dec 2006 | polycystic ovary syndrome | Federico II University | Completed | No outcome recorded |
| Phase 3 | NCT00511433 Comparator | Oct 2006 → Jan 2008 | — | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00413062 Comparator | Jun 2006 → Aug 2008 | — | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00511199 Comparator | May 2006 → Apr 2008 | — | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00356447 Comparator | May 2006 → Oct 2007 | vasomotor rhinitis | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00283816 Comparator | Jan 2006 → Jan 2008 | polycystic ovary syndrome | University of Rochester | Completed | No outcome recorded |
| Phase 4 | NCT06083935 Background | Nov 2023 → Aug 2024 | polycystic ovary syndrome | Ain Shams University | Unknown | No outcome recorded |
| Phase 4 | NCT06316180 Comparator | Jan → Aug 2023 | endometrial polyp | University of Palermo | Completed | No outcome recorded |
| Phase 4 | NCT03124524 Comparator | Jan 2015 → Sep 2016 | primary dysmenorrhea | Adana Numune Training and Research Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02855294 Comparator | Jan 2015 → Jul 2016 | — | Cairo University | Completed | No outcome recorded |
| Phase 4 | NCT01482338 Comparator | Jun 2011 → Feb 2012 | premenstrual tension | Chulalongkorn University | Completed | No outcome recorded |
| Phase 4 | NCT02342093 Background | Jan 2011 → Jul 2013 | hypertensive disorder | University of Sao Paulo | Completed | No outcome recorded |
| Phase 4 | NCT01109979 Comparator | Dec 2009 → Jan 2012 | cardiovascular disorder | Brigham and Women's Hospital | Completed | Met primary |
| Phase 4 | NCT00927095 Comparator | Jul 2008 → Jul 2014 | premenstrual dysphoric disorder | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 4 | NCT00617500 Comparator | Jul → Dec 2008 | — | Sociedade Hospital Samaritano | Unknown | No outcome recorded |
| Phase 4 | NCT00593294 Comparator | Jan 2006 → Sep 2007 | polycystic ovary syndrome | Federico II University | Completed | No outcome recorded |
| Phase 4 | NCT00640224 Comparator | Mar 2005 → Jul 2015 | polycystic ovary syndrome | Silva Arslanian | Completed | No outcome recorded |
| Phase 4 | NCT01511822 Comparator | — | polycystic ovary syndrome | AGUNCO Obstetrics and Gynecology Centre | Completed | No outcome recorded |
| — | NCT07242131 Comparator | Dec 2025 → Jun 2026 overdue | polycystic ovary syndrome | Ege University | Recruiting | No outcome recorded |
| — | NCT07229209 Comparator | Feb → May 2025 | uterine anomalies, uterine disorder | Benha University | Completed | No outcome recorded |
| — | NCT05872425 Background | Feb 2023 → Apr 2024 | polycystic ovary syndrome | Guangdong Women and Children Hospital | Completed | No outcome recorded |
| — | NCT01519401 Comparator | Feb 2010 → Jul 2011 | polycystic ovary syndrome | Catholic University of the Sacred Heart | Completed | No outcome recorded |
| — | NCT01432028 Comparator | Mar 2007 → Apr 2011 | — | Denusa Wiltgen | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2025-05-19 | ASKA Pharmaceutical Co., Ltd. | Regulatory 経口避妊剤 スリンダ錠28 製造販売承認取得のお知らせ aska-pharma.co.jp ↗ |
| 2024-11-13 | ASKA Pharmaceutical Co., Ltd. | Results 避妊を希望する日本人女性を対象としたLF111（ドロスピレノン）の国内第3相臨床試験結果に関する学会発表について aska-pharma.co.jp ↗ |
| 2024-06-24 | ASKA Pharmaceutical Co., Ltd. | Regulatory LF111（ドロスピレノン）の製造販売承認申請に関するお知らせ aska-pharma.co.jp ↗ |
| 2021-05-27 | Mayne Pharma International Pty Ltd | Regulatory Nextstellis ® Receives FDA Marketing Exclusivity and Phase III Data Published maynepharma.com ↗ |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-05-19 | ASKA Pharmaceutical Co., Ltd. | 経口避妊剤 スリンダ錠28 製造販売承認取得のお知らせ aska-pharma.co.jp ↗ |
| 2024-11-13 | ASKA Pharmaceutical Co., Ltd. | 避妊を希望する日本人女性を対象としたLF111（ドロスピレノン）の国内第3相臨床試験結果に関する学会発表について aska-pharma.co.jp ↗ |
| 2024-06-24 | ASKA Pharmaceutical Co., Ltd. | LF111（ドロスピレノン）の製造販売承認申請に関するお知らせ aska-pharma.co.jp ↗ |
| 2021-05-27 | Mayne Pharma International Pty Ltd | Nextstellis ® Receives FDA Marketing Exclusivity and Phase III Data Published maynepharma.com ↗ |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 129 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | drospirenone | “Participants received a monophasic combined oral contraceptive pills containing 0.03 mg ethinyl estradiol and 3 mg drospirenone (Technospiron® 0.03/3 mg, Technopharm, Egypt),...” NCT07229209 ↗120“15 mg estetrol and 3 mg drospirenone tablets administered once daily for 13 consecutive cycles following a 24/4-day regimen, i.e. one 15 mg E4/3 mg DRSP active tablet per day...” NCT02817841 ↗ “15 mg estetrol and 3 mg drospirenone tablets administered once daily for 13 consecutive cycles following a 24/4-day regimen, i.e. one 15 mg E4/3 mg DRSP active tablet per day...” NCT02817828 ↗ “Single-arm, Open-label, Interventional Study to Observe the Safety and Efficacy Profile of the Combined Oral Contraceptive YAZ®, a 24-day Cyclic Regimen Containing Drospirenone...” NCT02710708 ↗ “Combined oral contraceptive (COC; Yasmin; 0.03 mg ethinyl estradiol and 3 mg drospirenone); Subjects will start taking COC at / on the day of visit 2 and continue taking one...” NCT01254292 ↗ “OBJECTIVES: To investigate the long-term endometrial safety and bleeding pattern of the 0.25 mg drospirenone/0.5 mg 17β-estradiol (DRSP/E2) dose combination compared with 0.5...” PMID 23531117 ↗ May 2013 “The purpose of the study is to evaluate the effect of VX-407 on the pharmacokinetics of levonorgestrel (LNG) and ethinyl estradiol (EE), norgestimate (NGM) and EE,...” NCT07074327 ↗ “To evaluate the safety, compliance, and pharmacokinetics profile of estetrol monohydrate (E4) 15 mg combined with drospirenone (DRSP) 3 mg in post-menarchal participants...” NCT04792385 ↗ “Participants diagnosed with polycystic ovary syndrome (PCOS) during adolescence will receive a combined oral contraceptive (ethinylestradiol 30 µg + drospirenone 3 mg) once...” NCT07127458 ↗ “The objective of these study was to evaluate the effect of the use of a contraceptive containing 20 mcg of ethinyl estradiol and 3mg of drospirenone in the autonomic nervous...” NCT01590849 ↗ “Drospirenone and Ethinyl Estradiol Tablets, 3 mg DRSP and 30 mcg EE taken once daily from Day 1 of menstrual period up to and including Day 28 for 13 consecutive 28-day...” NCT00413062 ↗ |
| Known as | BAY 86-4891 | “E2/DRSP (BAY 86-4891) dose 1 (SH T04984E)” NCT00653614 ↗ |
| Known as | DROS | “Continuous daily oral drospirenone (DROS; 3mg) + ethinyl estradiol (EE; 20ug)” NCT00927095 ↗ |
| Known as | drospirenone and ethinylestradiol tablets (I) | “drospirenone and ethinylestradiol tablets (I) and (Ⅱ) will be used as an antiandrogen.” NCT04984070 ↗ |
| Known as | Drospirenone and Ethinylestradiol Tablets (Ⅱ) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05872425 ↗ |
| Known as | DRSP | “OBJECTIVE: To investigate the effects of an ethinylestradiol (EE) 20 μg/drospirenone (drsp) 3mg combined oral contraceptive (COC) administered in a 24/4 regimen (24 active...” PMID 21288628 ↗ Feb 201136“LPRI-CF113 consists of 24 active white tablets containing drospirenone (DRSP) 4 mg followed by 4 active pink tablets containing DRSP 2.8 mg, taken orally once daily for 28...” NCT05461573 ↗ “A recent study in Japanese patients with dysmenorrhea (NCT01892904) reported a significant reduction in the number of days with menstrual pain after treatment with a flexible...” PMID 32210639 ↗ Mar 2020 “The objective of this study is to compare the red blood cell (RBC) and plasma concentrations of folate in subjects treated with drospirenone (DRSP)/ethinyl estradiol (EE) plus...” NCT01902264 ↗ “OBJECTIVES: To investigate the long-term endometrial safety and bleeding pattern of the 0.25 mg drospirenone/0.5 mg 17β-estradiol (DRSP/E2) dose combination compared with 0.5...” PMID 23531117 ↗ May 2013 “The purpose of the study is to evaluate the effect of VX-407 on the pharmacokinetics of levonorgestrel (LNG) and ethinyl estradiol (EE), norgestimate (NGM) and EE,...” NCT07074327 ↗ “To evaluate the safety, compliance, and pharmacokinetics profile of estetrol monohydrate (E4) 15 mg combined with drospirenone (DRSP) 3 mg in post-menarchal participants...” NCT04792385 ↗ “The purpose of the study is to assess the effects of BMS-986278 on Drospirenone (DRSP) and Ethinyl Estradiol (EE) when administered as a combined oral contraceptive in healthy...” NCT05985590 ↗ “Drospirenone and Ethinyl Estradiol Tablets, 3 mg DRSP and 30 mcg EE taken once daily from Day 1 of menstrual period up to and including Day 28 for 13 consecutive 28-day...” NCT00413062 ↗ “To evaluate long-term effects of drospirenone (DRSP)/ethinylestradiol (EE) alone, metformin alone and DRSP/EE plus metformin on some cardiovascular risk factors in...” NCT01581814 ↗ “1 pill daily-24 days of drospirenone 3 mg (3 mg DRSP)/ethinyl estradiol 20 μg (20 μg EE)/levomefolate calcium 0.451 mg (folate) -followed by 4 days of levomefolate calcium...” NCT01360996 ↗ |
| Known as | E2/DRSP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00653614 ↗ |
| Known as | LF111 | “LF111 (drospirenone)” NCT02269241 ↗ |
| Known as | LF111 (drospirenone 4 mg tablet) | “LF111 (drospirenone 4 mg tablet)” NCT05303636 ↗ |
| Known as | LF1111 | “Drospirenone 4 mg tablet (LF1111)” NCT05303636 ↗ |
| Action | Inhibit | “The antiandrogenic property of drospirenone means that it blocks the male sex hormones that can cause acne.” NCT00722800 ↗ |
| Route | Oral | “given as tablets orally” NCT00102141 ↗ |